Search Results - "puli, Shilpa"

Abstract 4132223: Mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy: design of the Phase 3 SCOUT-HCM trial by Rossano, Joseph, Canter, Charles, Wolf, Cordula, Favatella, Nick, Lockman, Jeff, puli, Shilpa, Javidialsaadi, Atefeh, Dyme, Joshua, Crevar, Christina, Mital, Seema

“…Abstract only Background: While most current treatments can improve symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM), they may be poorly…”
Get full text

Abstract 12412: In Silico Evaluation of Dosing Regimens to Accommodate Coadministration of Mavacamten With Strong Inhibitors of Cytochrome P450 3A4 and Moderate Inhibitors of Cytochrome P450 2C19 in Patients With Obstructive Hypertrophic Cardiomyopathy by Merali, Samira, Bunn, Haden, Sychterz, Caroline, Chiang, Manting, puli, Shilpa, Sehnert, Amy J, Murthy, Bindu, Gobburu, Joga

“…Abstract only Background: Mavacamten is primarily metabolized by cytochrome P450 enzymes CYP2C19 and CYP3A4 and coadministration with strong CYP3A4 or moderate…”
Get full text

Intravenous Immunoglobulin (Privigen®) Has Similar Pharmacokinetic Properties in Primary and Secondary Immunodeficiency by Tortorici, Michael, Lawo, John-Philip, Jochems, Jeanine, Puli, Shilpa, Hofmann, Jutta, Pfruender, Dietmar, Rojavin, Mikhail

“…IgG PK was described well with a two-compartment model with mean (inter-individual coefficient of variation) estimates of 0.154 L/h (54%) for clearance and…”
Get full text

Similar Efficacy and Pharmacokinetic Behavior of Intravenous Immunoglobulin (Privigen®) in Primary and Secondary Immunodeficiency by Rojavin, Mikhail, Lawo, John-Philip, Jochems, Jeanine, Puli, Shilpa, Hofmann, Jutta, Pfruender, Dietmar, Tortorici, Michael

“…Efficiency Index was calculated as the difference between IgGtrough at steady-state dosing and pre-treatment IgG level at diagnosis (IgGendo) divided by…”
Get full text

Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency by Tortorici, Michael A., Lawo, John-Philip, Weide, Rudolf, Jochems, Jeanine, Puli, Shilpa, Hofmann, Jutta, Pfruender, Dietmar, Rojavin, Mikhail A.

“…Primary (PID) and secondary immune deficiencies (SID) represent diverse groups of diagnoses, yet both can be effectively treated with intravenous…”
Get full text

Effect of Combination Treatment of Rapamycin and Isoflavones on mTOR Pathway in Human Glioblastoma (U87) Cells by Puli, Shilpa, Jain, Aditi, Lai, James C. K., Bhushan, Alok

“…Glioblastoma Multiforme (GBM) is a malignant primary brain tumor associated with poor survival rate. PI3K/Akt pathway is highly upregulated in gliomas due to…”
Get full text

Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) Cells by isoflavones by PULI, Shilpa, LAI, James C. K, BHUSHAN, Alok

“…Glioblastoma multiforme is a primary brain tumor associated with extensive invasion into surrounding brain tissue. Matrix metalloproteinases (MMPs) and…”
Get full text

Signaling pathways mediating manganese-induced toxicity in human glioblastoma cells (u87) by Puli, Shilpa, Lai, James C K, Edgley, Kristina L, Daniels, Christopher K, Bhushan, Alok

“…Although essential, manganese (Mn) intake in excess leads to neurotoxicity. Mn neurotoxicity induces impairment of energy metabolism and ultimately cell death…”
Get full text

Regulation of invasion, signaling, and gene expression in human glioblastoma cells (U87): Effect of isoflavones, and manganese by Puli, Shilpa

“…Glioblastoma Multiforme (GBM) is a grade IV astrocytoma usually diagnosed in elderly patients. The survival rate of GBM patients is usually less than a year…”
Get full text